drugset / Trial / NCT03743285

A Study of an Automated Insulin Delivery System in Adult Participants With Type 1 Diabetes Mellitus (T1D)

NCT03743285

Completed 10 enrolled Eli Lilly and Company
NaSingle-groupOpen-labelDevice feasibility

Summary

The Automated Insulin Delivery (AID) System is an investigational insulin delivery device being developed for use for participants with diabetes. The purpose of this study is to assess the safety of the AID system and to test whether the AID System functions as designed. The study will last about 3 months with up to 6 days of inpatient time.

Timeline

Start
2018-11-14
Primary completion
2019-01-28
Completion
2019-01-28

Drugs

EvaluationDrugModalityDoseRoute
Background Insulin Lispro Protein / enzyme biologic Subcutaneous